Dexom also announces direct connectivity to the Apple Watch for its G7 continuous glucose monitoring (CGM) system through a dedicated Bluetooth connection.
Dexcom, a leader in glucose monitoring technology, has invested $75 million in Oura, the company behind the Oura Ring, as part of a strategic partnership to enhance metabolic health monitoring. This collaboration will enable seamless data integration between Dexcom’s continuous glucose monitors (CGMs) and the Oura Ring, providing users a comprehensive view of their health metrics.
The partnership plans to launch app integrations in the first half of 2025, allowing data to flow between Dexcom’s glucose biosensors and apps and the Oura Ring and its app. This integration will help users understand how behaviors and biological factors impact their metabolic health. Additionally, Dexcom and Oura will co-market and cross-sell each other’s products to reach a broader audience
Dexcom has expanded its offerings beyond traditional diabetes management by introducing Stelo, an over-the-counter continuous glucose monitor (CGM). Designed primarily for individuals with Type 2 diabetes not on insulin, Stelo also caters to those without diabetes who are interested in monitoring their glucose levels.
Dexxom has invested $75 million in ŌURA’s Series D funding round. This investment elevates ŌURA’s valuation to over $5 billion. In May 2021, Oura Health secured $100 million in a Series C funding round led by The Chernin Group and Elysian Park Ventures, bringing its total funding to $148.3 million. By April 2022, the company announced a valuation of $2.55 billion, following the sale of over one million Oura Rings.
In a strategic move showcasing its commitment to innovation, the company recently announced its third acquisition in just two years: Sparta Science. This cutting-edge platform specializes in collecting and analyzing crucial health and performance data.
Just a month prior, Oura made waves by agreeing to acquire Veri, a leader in personalized metabolic health programs that enhance individual wellness. Last year, the company made headlines with its all-equity acquisition of Proxy, a digital identification startup aiming to revolutionize security by replacing traditional keys, cards, badges, apps, and passwords with its advanced technology.
Further enhancing its product offering, the company unveiled two groundbreaking heart-health-monitoring features for the Oura Ring in May: Cardiovascular Age (CVA) and Cardio Capacity, empowering users with vital health insights.
The Cardiovascular Age (CVA) feature leverages data from the device to provide users with an insightful estimation of their cardiovascular age compared to their actual age, helping to highlight potential health areas for improvement.
Meanwhile, the Cardio Capacity tool offers valuable insights into overall cardiovascular health by estimating VO2Max, a critical measure of aerobic endurance that indicates how efficiently an individual can utilize oxygen during intense exercise. In June, Dexcom made strides in diabetes management by announcing direct connectivity to the Apple Watch for its G7 continuous glucose monitoring (CGM) system through a dedicated Bluetooth connection.
In March, the glucose monitoring company received FDA clearance for its over-the-counter CGM tool, Stelo. This innovative device can be purchased without a prescription and features a wearable biosensor that conveniently adheres to the back of the upper arm and has a remarkable battery life of up to two weeks.
